\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes Climate, Energy, Mobility Agro-Food, EnvironmentThe Flemish Government has provided 15,88 million euros subsidies for the new project call of the G-STIC Climate Action Programme. G-STIC, the Global Sustainable Technology and Innovation Community, aims to accelerate market-ready integrated technological solutions in view of contributing to the Sustainable Development Goals.
The G-STIC Climate Action Programme supports developing countries in their fight against climate change. This programme provides subsidies for demonstration, dissemination and capacity building projects in which Flemish organisations participate.
More information about the programme is available here.
G-STIC organises an online matchmaking event on 17-18 May, offering the opportunity to find and meet potential project partners.The event is open to those both offering and seeking climate solutions for developing countries. Participation is free of charge but it is mandatory to register here.
To support developing countries in the fight against climate change, the Flemish Government launched in 2021 the G-STIC Climate Action Programme, a call for proposals that provides international climate finance in line with the Paris Agreement. The G-STIC Climate Action Programme aims to strengthen developing countries' implementation of climate policies, strategies, regulations and action plans.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
